Hence, the small-molecule inhibitors appear to not only amplify the activity of low-potency antibodies on ErbB2-overexpressing tumours, but also exert toxicity on cells from tissues with low ErbB2 expression levels, leading inevitably to adverse side effects. The gene discussed is ERBB2; the disease is neoplasm.